Ticker > Company >

Ind-Swift Lab. share price

Ind-Swift Laboratories Ltd.

NSE: INDSWFTLAB BSE: 532305 SECTOR: Pharmaceuticals & Drugs  35k   44   6

99.14
+4.72 (5.00%)
NSE: Today, 01:32 PM

Price Summary

Today's High

₹ 99.14

Today's Low

₹ 92.6

52 Week High

₹ 186

52 Week Low

₹ 86.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

585.79 Cr.

Enterprise Value

165.62 Cr.

No. of Shares

5.91 Cr.

P/E

1.55

P/B

0.58

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  170.51

CASH

425.73 Cr.

DEBT

5.57 Cr.

Promoter Holding

42 %

EPS (TTM)

₹  63.93

Sales Growth

6.54%

ROE

59.2 %

ROCE

55.54%

Profit Growth

885.1 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.54%
3 Year12.74%
5 Year11.12%

Profit Growth

1 Year885.1%
3 Year359.67%
5 Year61.08%

ROE%

1 Year59.2%
3 Year22.35%
5 Year12.12%

ROCE %

1 Year55.54%
3 Year25.23%
5 Year17.99%

Debt/Equity

0.006

Price to Cash Flow

-3.26

Interest Cover Ratio

12.3018

CFO/PAT (5 Yr. Avg.)

0.924159116286285

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 42.00 0.00
Jun 2024 42.00 0.00
Mar 2024 42.00 48.57
Dec 2023 42.00 86.84
Sep 2023 42.00 86.84
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 838.1009 Cr.
  • Company has been maintaining healthy ROE of 22.3481763289909% over the past 3 years.
  • Company has been maintaining healthy ROCE of 25.2260510348175% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.3018.
  • Company’s PEG ratio is 0.00175204066526216.
  • The company has an efficient Cash Conversion Cycle of 9.8327 days.
  • Company has a healthy liquidity position with current ratio of 3.0593.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.6724251774773.

 Limitations

  • The company has shown a poor revenue growth of 12.7360483270744% for the Past 3 years.
  • Company has negative cash flow from operations of -179.768.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 270.3 276.28 381.73 30.46 2.71
Total Expenditure 206.9 222.04 309.22 34.99 14.71
Operating Profit 63.4 54.24 72.51 -4.53 -12
Other Income 7.4 7.11 25.25 11.14 12.95
Interest 21.14 21.05 -11.48 0.17 0.41
Depreciation 13.19 13.56 12.67 0.25 0.22
Exceptional Items 0 0 386.59 0 0
Profit Before Tax 36.47 26.75 483.15 6.19 0.32
Tax 6.38 5.09 133.57 0 0
Profit After Tax 30.1 21.66 349.59 6.19 0.32
Adjusted EPS (Rs) 5.09 3.66 59.17 1.05 0.05

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 751.84 856.58 988.09 1151.96 1227.32
Total Expenditure 610.78 676.1 794.38 929.86 977.35
Operating Profit 141.06 180.48 193.71 222.09 249.97
Other Income 36.08 23.13 42.5 33.28 45.31
Interest 106.65 100.2 95.55 92.17 51.1
Depreciation 90.06 87.29 130.97 57.36 53.3
Exceptional Items 0 0 -1.69 -26.65 386.59
Profit Before Tax -19.56 16.12 8 79.2 577.47
Tax 1.23 20.52 13.7 36.73 159.08
Net Profit -20.79 -4.4 -5.71 42.47 418.39
Adjusted EPS (Rs.) -3.52 -0.74 -0.97 7.19 70.81

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 59.81 59.81 59.81 59.81 59.09
Total Reserves 584.8 578.89 572.75 615.54 863.16
Borrowings 890.89 875.41 839.07 744.43 3
Other N/C liabilities -62.56 -42.46 -32.7 -11.41 -30.61
Current liabilities 309.29 286.72 313.61 350.05 178.32
Total Liabilities 1782.23 1758.36 1752.53 1758.42 1072.95
Assets
Net Block 842.93 737.64 626.79 585 5.32
Capital WIP 3.8 10.7 9.31 7.71 0
Intangible WIP 7.65 8.14 1 0 0
Investments 26.36 55.33 110.68 85.12 165.94
Loans & Advances 56.92 65.97 3.89 4.1 353.84
Other N/C Assets 0 14.77 4.72 3.82 2.3
Current Assets 844.56 865.8 996.15 1072.67 545.54
Total Assets 1782.23 1758.36 1752.53 1758.42 1072.95
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -19.56 16.12 9.69 105.85 190.88
Adjustment 176.02 179.35 225.59 132.78 124.76
Changes in Assets & Liabilities -33.3 -60.43 -99.02 -55.95 -495.41
Tax Paid 0 0 0 0 0
Operating Cash Flow 123.16 135.03 136.26 182.67 -179.77
Investing Cash Flow -10.15 -10.17 2.76 -13.69 -104.32
Financing Cash Flow -133.26 -123.75 -139.59 -168.41 699.86
Net Cash Flow -20.25 1.11 -0.57 0.58 415.77

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 42.00 42.00 42.00 42.00 42.00
bhanavi mehta 0.01 0.01 0.01 0.01 0.01
divya munjal 0.01 0.01 0.01 0.01 0.01
essix biosciences limited... 21.71 21.71 37.79 37.79 37.79
gopal munjal 0.10 0.10 0.10 0.10 0.10
himanshu jain 0.69 0.69 0.69 0.69 0.69
ishav mehta 0.01 0.01 0.01 0.01 0.01
late neera mehta - - - - 0.42
meenakshi mehta 0.02 0.02 0.02 0.02 0.02
n.r. munjal 1.56 1.56 1.56 1.56 1.56
neeta munjal 0.02 0.02 0.02 0.02 0.02
nidhi munjal 0.02 0.02 0.02 0.02 0.02
ravi mehta 0.02 0.02 0.02 0.02 0.02
rishav mehta 0.77 0.77 0.77 0.77 0.77
s. r. mehta 0.40 0.40 0.40 0.40 0.40
sahil munjal 0.01 0.01 0.01 0.01 0.01
sunita jain 0.08 0.08 0.08 0.08 0.08
v.r. mehta 0.09 0.09 0.09 0.09 0.09
neera mehta 0.42 0.42 0.42 0.42 -
ind swift ltd. 16.08 16.08 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 58.00 58.00 58.00 58.00 58.00
ashokkumar chandak 3.15 3.40 3.70 3.83 3.83
conquer investment & fina... 1.35 1.18 1.18 1.18 1.18
giriraj ratan damani - - - - 1.09
investor education and pr... - 0.26 0.26 - 0.26
llp - - - - 0.14
panjatan real estate priv... - - - - 1.35
sharwan singh guleria - - - 1.24 1.61
sri ganesh biotech privat... 1.18 1.35 1.35 1.35 1.35
wilson holdings private l... - - 11.75 9.93 9.20
anirudh damani - - - 1.03 -
investor education and pr... 0.26 - - 0.26 -
patanjali real estate pro... - - - 1.07 -
ec special situations fun... 6.82 6.56 2.78 - -
edelweiss india special s... 10.43 10.02 4.32 - -
edelweiss india special s... 2.24 2.16 - - -

Ratings & Research Reports

Company Presentations

Company News

Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM IND-Swift Laboratories informs about press release 23 Sep, 11:43 AM Ind-Swift Laboratories sets up new marketing office in New Delhi 23 Sep, 11:19 AM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Laboratories incorporates wholly owned subsidiary in UAE 20 May, 12:12 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Laboratories to incorporate wholly owned subsidiary in UAE 19 Apr, 12:15 PM Ind-Swift Laboratories informs about acquisition 19 Apr, 11:29 AM Ind-Swift Laboratories informs about disclosure 4 Apr, 10:02 AM Ind-Swift Laboratories informs about disclosure 3 Apr, 5:01 PM Ind-Swift Laboratories informs about disclosure 3 Apr, 12:15 PM Ind-Swift Laboratories informs about disclosure 30 Mar, 3:31 PM Ind-Swift Laboratories informs about disclosure 28 Mar, 10:58 AM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Laboratories informs about disclosure 8 Feb, 2:51 PM Ind-Swift Laboratories collaborates with CSIR- IMTECH 30 Nov, 9:36 AM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:18 PM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:01 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Laboratories gets nod to sell API Business to Synthimed Labs 6 Sep, 2:30 PM Ind-Swift Laboratories informs about outcome of board meeting 31 Aug, 5:00 PM Ind-Swift Lab. - Quaterly Results 9 Aug, 7:17 PM Ind-Swift Lab. - Quaterly Results 9 Aug, 7:17 PM Ind-Swift Laboratories informs about interest payment 22 Jun, 1:30 PM Ind-Swift Laboratories informs about updates 1 Jun, 2:28 PM Ind-Swift Lab. - Quaterly Results 29 May, 6:46 PM Ind-Swift Laboratories gets nod to sell M/s. Halcyon life Sciences 31 Mar, 10:29 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 5:35 PM Ind-Swift Laboratories wins ‘Asia's best Company for the year 2022’ award 27 Dec, 2:58 PM Ind-Swift Laboratories informs about loss of original share certificate 10 Nov, 12:41 PM Ind-Swift Lab. - Quaterly Results 8 Nov, 6:17 PM Ind-Swift Lab. - Quaterly Results 8 Nov, 6:17 PM Ind-Swift Laboratories informs about closure of trading window 29 Sep, 5:20 PM Ind-Swift Lab. - Quaterly Results 10 Aug, 8:05 PM Ind-Swift Laboratories enters into joint venture to explore opportunities in pharmaceutical field 24 Jun, 10:21 AM Ind-Swift Laboratories informs about compliance certificate 22 Apr, 4:47 PM Ind-Swift Lab. - Quaterly Results 8 Feb, 5:36 PM Ind-Swift Lab. - Quaterly Results 8 Feb, 5:36 PM Ind-Swift Lab. - Quaterly Results 8 Feb, 5:36 PM Ind-Swift Laboratories informs about disclosure 22 Sep, 4:21 PM Ind-Swift Laboratories informs about outcome of board meeting 31 Jul, 11:13 AM Ind-Swift Laboratories informs about disclosure 16 Jul, 12:01 PM Ind-Swift Laboratories informs about annual secretarial compliance report 8 Jun, 10:19 AM Ind-Swift Laboratories informs about cessation of independent director 25 Mar, 1:12 PM

Ind-Swift Lab. Stock Price Analysis and Quick Research Report. Is Ind-Swift Lab. an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ind-Swift Lab. and its performance over the period of time. Ind-Swift Lab. stock price today is Rs 99.14.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ind-Swift Lab. cash from the operating activity was Rs -179.768 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ind-Swift Lab. has a Debt to Equity ratio of 0.006 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ind-Swift Lab. , the EPS growth was 885.0906 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ind-Swift Lab. has OPM of 20.3668405417341 % which is a good sign for profitability.
     
  • ROE: Ind-Swift Lab. have a healthy ROE of 59.2007 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ind-Swift Lab. is Rs 99.14. One can use valuation calculators of ticker to know if Ind-Swift Lab. share price is undervalued or overvalued.
Last Updated on:
Brief about Ind-Swift Lab.
X